ReviewCells2023
Pulmonary Sequelae of COVID-19: Focus on Interstitial Lung Disease.
Review in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Efficacy and Safety of Pirfenidone for Mitigation of Interstitial Lung Abnormalities in COVID-19 Patients: A Meta-Analysis.Canadian respiratory journal · 2026Pooled it
- Catalase: A Potential Pharmacologic Target for Hydrogen Peroxide in the Treatment of COVID-19.Current topics in medicinal chemistry · 2024Pooled it
- Oral corticosteroid dosing strategies for post-COVID-19 organising pneumonia: NORCOVID clinical trial.ERJ open research · 2026Article
- Host-Pathogen Interactions Leading to Pneumonia Pathogenesis.Clinics in chest medicine · 2026Review
- Sex-specific trends in incidence and mortality of interstitial lung disease and pulmonary sarcoidosis in China compared with global estimates, 1990-2023: an analysis of GBD 2023.Journal of thoracic disease · 2026Article
- Clinical Evolution of a Cohort of Patients with COVID-19 Treated with Usual Medical Care Plus Polymerized Type I Collagen During the Pandemic Emergency.Medical sciences (Basel, Switzerland) · 2026Article
- Multimodal Autoencoder-Based Anomaly Detection Reveals Clinical-Radiologic Heterogeneity in Pulmonary Fibrosis.Medical sciences (Basel, Switzerland) · 2026Article
- Prognostic value of HRCT-based risk stratification for acute/subacute progression in polymyositis/dermatomyositis-associated interstitial lung disease.Frontiers in immunology · 2026Article
- Impact of Dexamethasone on Respiratory Sequelae in the Follow-Up of Hospitalized Patients with Sars-Cov-2 Pneumonia.Infection and drug resistance · 2026Article
- The Role of High-Resolution Lung Computed Tomography to Distinguish Between Fibrosing Hypersensitivity Pneumonitis and Usual Interstitial Pneumonia.Life (Basel, Switzerland) · 2025Article
- Scars from the pandemic: understanding post-COVID-19 interstitial lung disease.Breathe (Sheffield, England) · 2025Review
- Clinical outcomes of persistent cough following coronavirus disease 2019 infection: A 1-year retrospective cohort study.Asia Pacific allergy · 2025Article
- Organizing pneumonia in hospitalized COVID-19 patients: risk factors and long-term outcomes.Pneumonia (Nathan Qld.) · 2025Article
- Integrating CT radiomics and clinical features using machine learning to predict post-COVID pulmonary fibrosis.Respiratory research · 2025Article
- Long-Term Clinical Outcomes of Adults Hospitalized for COVID-19 Pneumonia.Emerging infectious diseases · 2025Observational
- Cytoimmunological Profile of Lower Airways in Post-COVID-19 Syndrome (PCS): Predictive Value of Bronchoalveolar Lavage.Journal of clinical medicine · 2025Article
- Protein profiling in intensive care unit-treated COVID-19 patients identifies biomarkers of residual lung abnormalities.ERJ open research · 2025Article
- Impact of Pulmonary Comorbidities on COVID-19: Acute and Long-Term Evaluations.Journal of clinical medicine · 2025Review
- Long COVID and Lung Involvement: A One-Year Longitudinal, Real-Life Study.Medicina (Kaunas, Lithuania) · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the world transitions from the acute phase of the COVID-19 pandemic, a novel concern has arisen-interstitial lung disease (ILD) as a consequence of SARS-CoV-2 infection. This review discusses what we have learned about its epidemiology, radiological, and pulmonary function findings, risk factors, and possible management strategies. Notably, the prevailing radiological pattern observed is organising pneumonia, with ground-glass opacities and reticulation frequently reported. Longitudinal studies reveal a complex trajectory, with some demonstrating improvement in lung function and radiographic abnormalities over time, whereas others show more static fibrotic changes. Age, disease severity, and male sex are emerging as risk factors for residual lung abnormalities. The intricate relationship between post-COVID ILD and idiopathic pulmonary fibrosis (IPF) genetics underscores the need for further research and elucidation of shared pathways. As this new disease entity unfolds, continued research is vital to guide clinical decision making and improve outcomes for patients with post-COVID ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.